Configure, sample and produce your supplement range in one place.
At a glance
- Format suitability
- Reviewed for gummies — confirmed per project.
Why brands use it
Why brands use Menaquinone-7
Menaquinone-7 is an essential vitamin commonly considered for daily-wellness ranges, sitting in the fat-soluble vitamins family. On DAT Supply briefs the positioning is set by the brand brief and reviewed against the target market’s claim rules — we do not pre-position an active for any single benefit. Editorial framing uses only EU 432/2012- or DSHEA-compatible wording — we never promote unauthorised claims, even when the active has consumer-side momentum. Format-wise we have considered Menaquinone-7 for gummies; the per-format formulation notes below describe the live constraints (taste, payload, stability, packaging) we tune in the formulation pass. Sourcing form (extract ratio for botanicals, salt or chelate form for minerals, free-form vs ester for amino acids) is reviewed against the brief, with documentation matched to the target market’s import rules. Inclusion rate and claim wording are reviewed per project — we don’t publish off-the-shelf doses.
FormulationHow we use Menaquinone-7 in formulas
A public-safe formulation reference — how this active behaves in our
formats, common pairings and handling notes. Final formulation, dose and
on-pack copy are confirmed per project.
- Heat stable
- Limited — use coated forms
- Soluble in matrix
- Conditional
- Vegan supply
- Project-specific
Claim wordingEU-authorised health claims
EU-authorised wording for this ingredient is reviewed per project against Reg. 1924/2006 and the authorised list under Reg. 432/2012. No final claim wording is implied by this page.
Across the EU and UK markets Menaquinone-7 is treated as a vitamin: any on-pack benefit wording must come from the EU 432/2012 register (UK retains the same wording post-Brexit), and the inclusion rate has to meet the minimum thresholds tied to the chosen claim. For the US market, label benefit copy follows DSHEA structure-function rules with the standard "not intended to diagnose, treat, cure or prevent any disease" disclosure. We never reuse a market’s wording as if it carried over — claim copy is rewritten per market and reviewed per project. Country-level rules (e.g. France, Italy, Belgium for the EU; California Prop 65 for the US) layer on top, and the back-of-pack nutritional table is built against the market’s reference intake framework.
EU-authorised health claims Authorised at ≥15% NRV per daily serving. Claim wording must appear verbatim on consumer packaging. DAT reviews final pack copy per project against EU 1924/2006 and the authorised list under EU 432/2012.
Serving
Typical serving and reference level
Where the serving level for Menaquinone-7 is set, and who sets it. The
figure that reaches your label is fixed against the specification for your
formula and your market — not read off this page.
- Measured in
- mcg
Reference level Typical anchor: mcg per serving — confirmed per project.
Menaquinone-7 is measured by weight (mcg) per serving on DAT Supply briefs. The working anchor — the inclusion rate against which target-market claim wording is reviewed — is set during the formulation pass for each project rather than published as a fixed number on the public page. Final per-serving load depends on the chosen format (gummy payload window, capsule fill weight, softgel oil load, sachet or powder scoop size, oral-liquid bottle geometry) and the claim wording the brand needs to support against the target market. Sourcing form (extract ratio, standardised marker, micronised vs granular, salt or chelate form) is reviewed in the same pass. Country-level upper limits (France, Italy, Belgium for the EU; California Prop 65 for the US) are checked before any inclusion rate is finalised. Dose is confirmed per project — we don’t publish off-the-shelf dose tables for any active in the catalogue.
Research library
The evidence behind Menaquinone-7
8 studies relevant to Menaquinone-7, strongest
evidence first. Peer-reviewed sources and regulatory opinions. Citations only — DAT cites
the science, it does not endorse the publishers. Studies are on the ingredient, not on any
finished product.
Menaquinone-7Peer-reviewed studyStrong evidence
The role of vitamin K in bone and cardiovascular health
- Population
- Review
Review article detailing the molecular mechanism of vitamin K-dependent carboxylation of osteocalcin and matrix GLA protein.
Menaquinone-7Peer-reviewed studyModerate evidence
Effect of menaquinone-7 supplementation on arterial stiffness in healthy postmenopausal women: a double-blind randomized clinical trial
- Population
- Postmenopausal women (n=244)
- Studied dose
- 180 mcg/day MK-7
- Duration
- 3 years
Double-blind RCT in healthy postmenopausal women found that MK-7 (180 mcg/day for 3 years) significantly improved arterial stiffness (carotid-femoral pulse wave velocity) compared to placebo.
Menaquinone-7Peer-reviewed studyModerate evidence
Vitamin K2 supplementation improves hip bone geometry and bone strength indices in postmenopausal women
- Population
- Postmenopausal women (n=244)
- Studied dose
- 45 mcg/day MK-7
- Duration
- 3 years
Randomized controlled trial in postmenopausal women showed that MK-7 supplementation (45 mcg/day for 3 years) improved bone mineral density and bone strength.
Menaquinone-7Peer-reviewed study
Comparison of menaquinone-4 and menaquinone-7 bioavailability in healthy men
- Population
- Healthy men (n=12)
- Studied dose
- Single dose of 1 mg MK-7 vs MK-4
- Duration
- Single dose, 72h follow-up
MK-7 has superior bioavailability and longer half-life compared to MK-4, supporting once-daily dosing.
Menaquinone-7Peer-reviewed study
Effect of menaquinone-7 on vascular calcification in patients with chronic kidney disease: a randomized controlled trial
- Population
- Chronic kidney disease patients (n=200)
- Studied dose
- 90 mcg/day MK-7
- Duration
- 12 months
RCT showing MK-7 (90 mcg/day) reduced progression of arterial stiffness in CKD patients.
Menaquinone-7Peer-reviewed study
Menaquinone-7 supplementation to reduce vascular calcification in patients with coronary artery disease: a randomized controlled trial
- Population
- Patients with coronary artery disease (n=60)
- Studied dose
- 360 mcg/day MK-7
- Duration
- 6 months
MK-7 (360 mcg/day) for 6 months reduced arterial stiffness and improved cardiovascular health markers in patients with coronary artery disease.
Menaquinone-7Peer-reviewed study
Safety and tolerability of menaquinone-7 in healthy adults: a 12-week randomized controlled trial
- Population
- Healthy adults (n=40)
- Studied dose
- 1000 mcg/day MK-7
- Duration
- 12 weeks
MK-7 at doses up to 1000 mcg/day for 12 weeks was well tolerated with no adverse effects on coagulation.
Menaquinone-7Peer-reviewed study
The role of vitamin K in bone and cardiovascular health
- Population
- N/A
- Studied dose
- N/A
- Duration
- N/A
Review detailing activation of osteocalcin and MGP by vitamin K, emphasizing MK-7's longer half-life.
The formulas above sit in these private-label ranges:
Adjacent actives
Ingredients that sit alongside this one
Start Build a formula around Menaquinone-7
Explore the private-label options that use Menaquinone-7 — review formula, format and packaging on each product before you commit.
